ClinicalTrials.Veeva
Menu

Find clinical trials for Adenocarcinoma in Paris, Île-de-France

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Pancreatic Cancer
Colorectal Cancer
Non-Small-Cell Lung Carcinoma
Stomach Cancer
Prostatic Cancer
Esophageal Cancer
Neoplasm Metastasis

Adenocarcinoma trials near Paris, Île-de-France, FRA:

Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC) (RASolute 304)

The purpose of this study is to evaluate the safety and efficacy of a novel RAS(ON) inhibitor compared to standard of care (SOC) observation only.

Enrolling
Resected Pancreatic Adenocarcinoma
PDAC - Pancreatic Ductal Adenocarcinoma
Drug: daraxonrasib

Phase 3

Revolution Medicines
Revolution Medicines

Villejuif, Val-De- Marne, France and 33 other locations

Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)

with HER2-positive gastric or gastro-esophageal junction (GEJ) adenocarcinoma who have progressed on or after a trastuzumab-containing regim...

Active, not recruiting
Gastric Cancer, Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
Drug: Ramucirumab
Drug: Paclitaxel

Phase 3

Daiichi Sankyo
Daiichi Sankyo

Paris, France and 155 other locations

Oxaliplatin ± Nivolumab in Combination With Trifluridine/Tipiracil or 5-fluorouracile in Frail Patients With Advanced, Recurrent or Metastatic Gastric, Oesophageal or Gastroesophageal Junction Cancer (LOGICAN)

Oxaliplatin ± nivolumab in combination with trifluridine/tipiracil or 5-fluorouracile (5-FU) in frail patients with advanced, recurrent or metastatic...

Enrolling
Esophagus Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
Drug: Nivolumab
Drug: FOLFOX regimen

Phase 2

Unicancer
Unicancer

Paris, France and 29 other locations

A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015) (TroFuse-015)

(TPC) in participants with advanced/metastatic gastroesophageal adenocarcinoma. The primary hypothesis of this study is sacituzumab tirumote...

Active, not recruiting
Gastroesophageal Cancer
Drug: Supportive care measures
Biological: Sacituzumab tirumotecan

Phase 3

Merck Sharp & Dohme (MSD)
Merck Sharp & Dohme (MSD)

Paris, Île-de-France Region, France and 168 other locations

Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2

(CLDN18.2)-positive, human epidermal growth factor receptor 2 (HER2)-negative, gastric, gastroesophageal junction (GEJ), and esophageal adenocarcinoma...

Enrolling
Gastroesophageal Junction Adenocarcinoma
Esophageal Cancer
Drug: Sonesitatug vedotin
Drug: Nivolumab

Phase 3

AstraZeneca
AstraZeneca

Villejuif, France and 268 other locations

Sotorasib Combined With First-line Chemotherapy for Advanced Pancreatic Adenocarcinoma (PANSOTO)

objective of this trial is to evaluate the safety and tolerability of sotorasib combined with first-line chemotherapy for advanced pancreatic adenocarcinoma...

Enrolling
Pancreatic Adenocarcinoma
Drug: Sotorasib, 960 mg, oral daily dose for 4 weeks (28 days)

Phase 1

Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)

Villejuif, France, France and 26 other locations

Study of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma (PRISM-1)

The purpose of this study is to compare overall survival of quemliclustat, nab-paclitaxel and gemcitabine versus placebo, nab-paclitaxel and gemcitab...

Active, not recruiting
Metastatic Pancreatic Ductal Adenocarcinoma
Drug: Gemcitabine
Drug: Nab-paclitaxel

Phase 3

Arcus Biosciences
Arcus Biosciences

Villejuif, France and 118 other locations

Safety and Efficacy of Mitazalimab in Combination With Chemotherapy in Pancreatic Cancer Patients (OPTIMIZE-1)

Phase 1b/2 study to assess the safety and efficacy of mitazalimab in combination with chemotherapy in patients with metastatic pancreatic ductal adenocarcinoma...

Active, not recruiting
Metastatic Pancreatic Ductal Adenocarcinoma
Biological: CD40 agonist mitazalimab in combination with chemotherapy

Phase 1, Phase 2

Alligator Bioscience

Paris, France and 13 other locations

Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) (RASolute 302)

The purpose of this study is to evaluate the safety and efficacy of a novel RAS(ON) inhibitor compared to standard(s) of care (SOC) treatment.

Active, not recruiting
PDAC - Pancreatic Ductal Adenocarcinoma
PDAC
Drug: 5-fluorouracil
Drug: leucovorin

Phase 3

Revolution Medicines
Revolution Medicines

Villejuif, France and 59 other locations

Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)

esophageal adenocarcinoma.This substudy will have two phases: a safety lead-in phase and an efficacy phase. The safety lead-in phase will b...

Enrolling
Gastroesophageal Adenocarcinoma
Esophageal Cancer
Drug: Levoleucovorin
Drug: 5-Fluorouracil (5-FU)

Phase 1, Phase 2

Merck Sharp & Dohme (MSD)
Merck Sharp & Dohme (MSD)

Paris, Île-de-France Region, France and 51 other locations

Clinical trials

Find clinical trialsTrials by location

Research sites

Find research sitesLearn about CTV for professionals

Resources

Contact CTV support

Legal

Privacy NoticeTerms
© Copyright 2026 Veeva Systems